Pendopharm, a division of Pharmascience, is a leading Canadian specialty pharmaceutical company dedicated to developing, in-licensing and commercializing innovative products to improve the lives of Canadian patients and their families. Areas of Interest – Rare Diseases – Gastroenterology – Sports Medicine & Orthopedics – Neurology Building off a base of established medicines, offering more than 40 products across multiple therapeutic areas we have added new and exciting products. At Pendopharm, we are actively seeking strategic partnerships for commercial and late stage clinical assets for Canada and select international markets. With our proven track record, well-established commercial infrastructure and strong financial capabilities, we are uniquely positioned to maximizing the full potential of your products. Our Strengths – Proven Track Record of Profitability and Stability – Broad Experience Across Multiple Therapeutic Areas – In house cross functional expertise – CDMO capability through sister company
PatSnap
Patsnap empowers IP and R&D teams by providing better answers, so they can make faster decisions with more confidence. Founded in 2007, Patsnap is the global leader in AI-powered IP and R&D intelligence. Our domain-specific LLM, trained on our extensive proprietary innovation data, pairs seamlessly with our AI assistant, Hiro, to deliver insights that drive results—boosting IP productivity by 75% and cutting R&D wastage by 25%. IP and R&D teams collaborate better with a user-friendly platform across the entire innovation lifecycle. Over 15,000 companies trust Patsnap to innovate faster with AI, including NASA, PayPal, Sanofi, Dow Chemical, and Wilson Sonsini. | Founded in Singapore in 2007, PatSnap is a global leading innovation intelligence company. Leveraging domain-specific AI agents and robust analytics tools, PatSnap empowers IP and R&D teams to unlock insights, accelerate discoveries and protect breakthroughs. Trusted by more than 15,000 enterprises, law firms and research institutions in over 50 countries including one-third of the world’s largest R&D spenders, Patsnap transforms how organizations innovate and make critical decisions. Learn more at www.patsnap.com.
NINTX – Next Innovative Therapeutics
Nintx sees plant-based natural products as the best platform to develop multi-target therapies against multifactorial diseases as they can modulate targets directly and indirectly via gut microbiome. | Nintx (Next Innovative Therapeutics) was originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants, microorganisms, and humans) into novel therapies with environmental and social impact. To that end, Nintx has established partnerships with research institutes, private companies and investment funds that bring both complementary expertise and financial resources. Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil, targeting multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Nintx owns cutting-edge proprietary technologies, an Agentic AI platform (GAIApath®️) and an artificial gut (xGIbiomics®️), that enable the development of innovative ingredients (pharmaceuticals and nutraceuticals).
Neolpharma
Neolphama is a Mexican Pharmaceutical Corporation, made up of different specialized business units dedicated to research and development of high quality drugs contributing to better human health. | Top Mexican Pharma company, with presence in over 14 countries throughout the LATAM region.
Midas Pharma
One Partner – many Opportunities. Midas Pharma is a mid-sized pharmaceutical company, founded 1988 and based in Ingelheim, Germany. Midas offers products, services and expertise along the entire pharmaceutical value chain – from Starting Materials and Active Pharmaceutical Ingredients to market-ready Finished Products and Devices. Since over three decades the family-owned company has successfully contributed to the Pharma sector and has step by step expanded its competencies. With more than 270 employees and 10 locations in all major pharmaceutical markets worldwide Midas Pharma has excellent local know-how, local contacts and well-established networks in different pharmaceutical sectors. Visit Midas Pharma at the German Pavilion and www.midas-pharma.com | Accelerate your development of Biologics and Drug Device Combinations and benefit from the experience and comprehensive pharmaceutical support to safeguard your project executions – from pre-clinic to commercial phase. Benefit from our experience and our wide-ranging portfolio, from cell-line development, CDMO, QM, RA, PV, QP, MA holder and supply chain management service, to complete your projects. Resilience your supply chains with our broad portfolio of biopharmaceutical ingredients and drug substances from R&D to commercial supply, as natural & unnatural Amino-acids, building blocks for Nucleic Acids (Nucleotides, Cap-analogues and Phosphoramidites) as well as Linkers & Payloads for drug conjugates. Ask us also about our customized solutions. Multiply your licensing opportunities for innovative developments. | Where innovation meets expertise – Midas Pharma is your all-in-one provider for biopharma Accelerate your development of Biologics and Drug Device Combinations and benefit from our expertise and tailored pharmaceutical support to safeguard your project executions – from drug discovery to commercial phase. Focus on your specific demands, whether it’s optimizing capacity or importing your product into the European Union, by using our pharma infrastructure: EU QP release services (in-house QPs), regulatory support incl. marketing authorization holdership and pharmacovigilance services (in-house EU-QPPV). Exploit our wholesale and supply chain expertise to import, launch and distribute your biopharmaceutical products. Speed up your drug discovery and development with our comprehensive bioanalytical services for mAbs, ADCs, peptides, and nucleic acids. We offer a wide range of cutting-edge analytical methods, e.g., for structural and functional characterization of proteins, lead & clone selection, and biosimilar studies. Resilience your supply chain with our broad portfolio of biopharmaceutical intermediates (Building blocks for TIDES, Linkers & Payloads etc.), produced at GMP-compliant sites. Discover Gx Inbeneo®, our next generation autoinjector, which addresses the challenges of subcutaneous self-administration of biopharmaceuticals with injection volumes of up to 3 ml and ultra-high viscosities. The constantly pre-pressurized system ensures smooth continuous injection with shortened injection times; a needle that is not in contact with the drug product prevents needle clogging. Gx Inbeneo® offers quick customization to different formulations for faster time-to-market. Midas Pharma advantages: – All-in-one provider with modular service offers, tailored to your needs – Collaboration from expert to expert – EU headquartered, with a global operational footprint | With more than 35 years of experience, Midas Pharma brings proven expertise to every stage of the biopharmaceutical product life cycle. As a fully-fledged pharmaceutical company with EU GMP/GDP/WDA and MIA licenses, we offer a complete and reliable infrastructure tailored to your needs, whether you are an innovative start-up or an established biopharmaceutical company. Combining scientific expertise with a robust global network, Midas Pharma delivers integrated end-to-end solutions that accelerate your path from early-stage R&D to market. We provide the insight, infrastructure, and commitment needed to achieve your goals with confidence and to succeed in the competitive biopharmaceutical landscape. Your key benefits: • Process development: Expertise in biotechnological and chemical processes, covering preclinical development to commercial manufacturing. • Analytical services: Comprehensive structural and functional analysis that delivers precise insights into your molecule; tailored solutions, aligning technical accuracy with strategic goals through a holistic approach. • Starting materials, intermediates, drug substance, drug product, fill and finish (non GMP and GMP quality): Robust supply chain, including documentation in compliance with the authority requirements worldwide. • Novel autoinjector platform: Innovative solutions that overcome key challenges in subcutaneous delivery – enabling the injection of small and large volumes, especially but not only for high concentrated biologics. • GMP services: From EU QP release to global import/export: guaranteeing your products meet all regulatory standards. • Market entry strategy: Guidance through the process of entering target markets, including due diligence and clinical trials. • Business Development Advisory Services: With our global network spanning mid‑ and top‑tier biopharma in the US, Europe, and Asia, we deliver expert advisory support to accelerate your partnering success. Our customized services include financial modeling and valuation, deal structuring, due diligence, partner identification, and contract negotiation empowering you to maximize shareholder value. • Commercial operations: Comprehensive wholesale solutions along with marketing authorization holder (MAH) and pharmacovigilance (PV) services. Analytical services powered by Biofidus – A member of the Midas Group
MIAS Pharma Ltd
MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs. Customers are small to medium Pharma / Bio-Pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the Quality/Regulator expertise to comply with complex EU regulations. MIAS Pharma delivers two main solutions: 1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace) 2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market. MIAS Pharma also provide oversight of: – European Qualified Person (QP) services – Regulatory compliance of manufacturing activities – Regulatory compliance of Repackaging / Relabeling services – Regulatory compliance of Shipment and Transportation activities – Compliance with responsibilities as a Market Authorisation Holder (MAH) MIAS operates in a hub and spoke model with a core group of MIAS employee being able to rely on a group of associated to flex up/down capacity depending on clients’ requirements. | MIAS Pharma Ltd was set up in 2016 to enable Pharma / Bio-Pharma companies to manufacture and import products into the EU / EEA in a compliant manner, at optimal cost, with no significant investment in licence application activities or office / personnel costs. Primary customers are small to medium Pharma / Bio-Pharma companies that look to enter the EU market but do not have required Manufacturing and Importation licence or the Quality/Regulator expertise to comply with complex EU / UK regulations. In recent times MIAS also supports CMOs, CROs, Packaging companies and Testing companies QP solutions to take the burden off internal resources. MIAS Pharma delivers two main solutions: 1. A licensing framework to enable pharmaceutical importation and batch certification (required before each batch of a medicine can be made available in the EU/EEA marketplace) 2. Qualified Person (QP) services to oversee the release of investigational medicinal product for Clinical Trials and commercial product to the market. MIAS Pharma also provides: 1. European & UK Qualified Person (QP & QA) services 2. QP Audit programs 3. QMS Design: WDA & MIA 4. Turnkey EU Launch solutions: Packaging, Labelling, Distribution & Testing (Via Alliances) 6. Support for IMPD and Market Authorisation (MA) submissions MIAS operates in a hub and spoke model with a core group of MIAS employees being able to rely on a group of international associates to flex up/down capacity depending on clients requirements. | MIAS Pharma Supports Companies to carry out both Clinical Studies and Commercial Product launches in Europe and the UK. We hold licences known as MIA’s which allow us to import and QP release your products. As part of our service offering we can support you with: – EU / UK set-up – We can support your IMPD / MA submissions – Via our partner companies we can support Market Access, commercialisation and Distribution – QP Release – Product testing and retains – Audit Programs – WDA and RP Services
Marjan Farma
We are a Brazilian pharmaceutical company with more than 60 years of history focused on offering health products to improve people’s quality of life and well-being. | Founded in 1961, Marjan Farma has been a trusted pharmaceutical industry for the past 62 years, developing, producing and marketing innovative products to improve patient health and well-being. | Founded in 1961, Marjan Farma has been a trusted pharmaceutical industry for the past 64 years, developing, producing and marketing innovative products to improve patient health and well-being.
Lee’s Pharmaceutical (HK) Limited
Lee’s Pharm is a research-driven and market-oriented biopharmaceutical company with 30 years of operation in the pharmaceutical industry in China. The Group is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China. The Company has established extensive partnerships with around 30 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm focuses on several key disease areas such as cardiovascular, woman health, pediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing of development, commercialization, and manufacturing rights from various United States, European and Japanese companies. For more information, please visit www.leespharm.com.
Laboratorios PISA SA de CV
PiSA® Farmacéutica is a 100% Mexican company with 80 years of history, developing comprehensive products and services for both the public and private healthcare sectors in Mexico, the United States, Latin America, and the Caribbean. For more than seven decades, PiSA® Farmacéutica has experienced consistent growth, driven by its human capital. We are committed to excellence, fully aware that each of our actions and activities is carried out in fulfillment of our purpose: “A Life in the Service of Life.” At PiSA® Farmacéutica, we are recognized for our production capacity and extensive experience in the Mexican and Latin American markets; this has enabled us to set the standard for our growth and international expansion.